Compare NRDY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | MGNX |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.7M | 115.8M |
| IPO Year | 2020 | 2013 |
| Metric | NRDY | MGNX |
|---|---|---|
| Price | $0.80 | $2.93 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $1.00 | ★ $3.40 |
| AVG Volume (30 Days) | 829.4K | ★ 1.5M |
| Earning Date | 05-07-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $8.64 | $16.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.99 |
| 52 Week High | $1.90 | $3.50 |
| Indicator | NRDY | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 58.32 |
| Support Level | $0.78 | $1.46 |
| Resistance Level | $0.99 | $3.50 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 14.06 | 27.22 |
Nerdy Inc operate a next-generation live tutoring and intervention platform that leverages the power of human expertise with Developed artificial intelligence (AI) to personalize learning, accelerate student achievement, and empower educators. The company's proprietary platform leverages technology, including AI, to connect learners with instructors across a wide range of subjects and formats, including subscription-based learning, one-on-one instruction, small group tutoring, large-format classes, and assessments. Its flagship business operates under the Varsity Tutors brand. The company's offerings are available directly to students and consumers, as well as through schools and other institutions.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.